HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

3D-QSAR, molecular docking studies, and binding mode prediction of thiolactomycin analogs as mtFabH inhibitors.

Abstract
Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthase III (mtFabH) has been identified as a novel target for treating tuberculosis. The aim of this study was to understand the binding affinities of thiolactomycin (TLM) analogs for mtFabH based on 3D quantitative structure-activity relationship (3D-QSAR) analysis and molecular docking studies. The 3D-QSAR models produced statistically significant results (comparative molecular field analysis (CoMFA) r2 cv = 0.701, r(2) = 0.988; comparative molecular similarity indices analysis (CoMSIA) r2 cv = 0.625, r(2) = 0.969) with 40 TLM analogs. In particular, compounds possessing hydrogen bond acceptors attached to the end of side chains at the C5 position of TLM analogs may enhance their activity. The results of 3D-QSAR models were further compared with structure-based analysis using docking studies with the crystal structure of mtFabH. A plausible binding mode between TLM analogs and mtFabH is proposed.
AuthorsXiaoyun Lu, Yadong Chen, Qidong You
JournalJournal of enzyme inhibition and medicinal chemistry (J Enzyme Inhib Med Chem) Vol. 25 Issue 2 Pg. 240-9 (Apr 2010) ISSN: 1475-6374 [Electronic] England
PMID19968566 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Bacterial Agents
  • Thiophenes
  • thiolactomycin
  • 3-ketoacyl-acyl carrier protein synthase III
  • 3-Oxoacyl-(Acyl-Carrier-Protein) Synthase
Topics
  • 3-Oxoacyl-(Acyl-Carrier-Protein) Synthase (antagonists & inhibitors, metabolism)
  • Animals
  • Anti-Bacterial Agents (chemistry, metabolism)
  • Binding Sites
  • Computer Simulation
  • Crystallography, X-Ray
  • Humans
  • Models, Molecular
  • Molecular Conformation
  • Mycobacterium tuberculosis (enzymology)
  • Protein Binding
  • Quantitative Structure-Activity Relationship
  • Thiophenes (chemistry, metabolism)
  • Tuberculosis (drug therapy)
  • User-Computer Interface

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: